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Summary 14 
Since the Journal was first published in 1975, papers addressing therapeutic drug monitoring (TDM) 15 
have been a regular feature. Initially they focused on laboratory aspects of drug concentration 16 
measurement then they changed more to the application of TDM in a clinical setting. Over its 17 
history, the Journal has provided its readership with the latest technological and scientific advances 18 
in TDM and has helped to drive changes in TDM that have directly impacted on patient care. These 19 
have varied from improvement in the quality of antimicrobial measurements through better 20 
identification of dosage regimens and TDM targets that help predict outcome and adverse events. 21 
Despite these advances in our understanding of the science and practice of TDM, there still remain 22 
many areas of uncertainty. As we move into the next 40 years, it is clear that the Journal will 23 
continue to provide the readership with the latest science and opinion in this important area.  24 
 25 
Article 26 
In the 40 years since the Journal was first published, the papers within it have reflected the cutting 27 
edge of therapeutic drug monitoring (TDM) in the field of antimicrobial chemotherapy and provide a 28 
ĨĂƐĐŝŶĂƚŝŶŐ ?ƌŽĂĚŵĂƉ ?ŝůůƵƐƚƌĂƚŝŶŐŚŽǁƚŚĞƐĐŝĞŶĐĞƵŶĚĞƌƉŝŶŶŝŶŐŝƚŚĂƐĚĞǀĞůŽƉĞĚ ?  29 
 30 
While TDM has traditionally been thought of as a process to help reduce the risk of adverse events in 31 
patients receiving toxic drugs, increasingly it is being recognised as important for optimising 32 
therapeutic outcomes, either in terms of cure or resistance suppression. However, irrespective of 33 
objectives, TDM relies on the rapid, and accurate, determination of drug levels in a patient with 34 
adjustment of dose if these are not consistent with the expected, or target, concentration ranges. 35 
  36 
In the early years of the Journal, there was a clear focus around practical aspects of therapeutic drug 37 
monitoring and laboratory support for the clinical use of antimicrobials1. This was largely driven by 38 
ƚŚĞŝŶĐƌĞĂƐŝŶŐƵƐĞŽĨƚŚĞĂŵŝŶŽŐůǇĐŽƐŝĚĞƐĂŶĚĚƵƌŝŶŐƚŚĞĨŝƌƐƚĚĞĐĂĚĞŽĨƚŚĞ:ŽƵƌŶĂů ?ƐƉƵďůŝĐĂƚŝŽŶ39 
there were frequent reports of methodological advancement. While early reports addressed 40 
developments of bioassays to shorten turnaround times and prevent interference from other 41 
ĂŐĞŶƚƐ ?ǁŝƚŚŝŶĂĨĞǁǇĞĂƌƐ ?ŶĞǁĂƉƉƌŽĂĐŚĞƐƐƚĂƌƚĞĚƚŽďĞƌĞƉŽƌƚĞĚ ?/ŶŝƚŝĂůůǇ ?ƚŚĞƐĞǁĞƌĞďĂƐĞĚ42 
around either bacterial enzymes (transferase assay) or growth (bioluminescence), but by the early 43 
1980s immunoassay reports dominated the publications2. These started with simple descriptions of 44 
the methods but very quickly shifted to publications reporting comparisons between the different 45 
assay systems as it became clear that these assays were highly specific, accurate and rapid3. While 46 
some of the assays reported in the early 1980s are no longer relevant, those based around 47 
homogeneous reactions largely remain in use to the current date. In the main, this change was 48 
driven by technological advances and commercial factors, but publications in the Journal highlighting 49 
the relative performance of such methods in external quality assessments certainly advanced the 50 
withdrawal of those methods that performed poorly4. 51 
 52 
During these early years, although there were significant advancements in the technology 53 
supporting delivery of TDM services, understanding of the targets and objectives for TDM largely 54 
lagged behind.  Aminoglycosides had long been known to have to have the potential for oto- and 55 
nephrotoxicity and during the early years of the Journal there were many studies reporting the 56 
incidence of toxicity of aminoglycosides5. These concerns over toxicity dominated TDM approaches 57 
for both aminoglycosides and other less toxic classes of antimicrobial6 and persist to the present day, 58 
However, although the first report of once daily administration of gentamicin appeared in the 59 
Journal in 19787 ?ŝƚǁĂƐŶ ?ƚƌĞĂůůǇƵŶƚŝůƚŚĞůĂte 1990s that TDM objectives became clearer thanks to 60 
the increasing volume of information coming from PK/PD analysis8. 61 
 62 
Immunoassay methods and liquid chromatography were introduced almost contemporaneously into 63 
the microbiology laboratory9. This was initially reflected in the Journal publications by 64 
methodological papers reporting assay conditions to measure different agents but rapidly developed 65 
during the early 1980s to reflect the application of these methods in a TDM setting. This started with 66 
reports describing their use in plasma pharmacokinetics of existing and the rapidly increasing 67 
number of new agents, but by the mid-1980s the focus had expanded to include studies of 68 
antimicrobial penetration into extra vascular sites10. While some of these studies addressed 69 
surrogates of penetration, such as the blister fluid or implanted thread methods, as frequently 70 
reported by Wise and colleagues11, increasingly the focus changed to penetration into tissues 71 
recovered during routine operations; particularly bone12. Most of the published studies reported 72 
data for low subject numbers (typically 5-10 subjects) and rarely presented information to support 73 
validation of the assay system. In the absence of any higher quality information, these penetration 74 
studies helped inform TDM and dosing approaches for non-vascular sites13. However, and especially 75 
in the case of the penetration studies, in more recent years the quality of some of the findings 76 
reported during this period has been questioned14. 77 
 78 
During the early 1980s, there was an increasing recognition that antimicrobial concentrations at the 79 
site of infection are important for outcome as well as the recognition that measures of free-drug 80 
rather than whole drug better predicted activity15. This led to an increasing number of papers 81 
describing the protein binding of antimicrobials; principally conducted in healthy volunteers using 82 
ultrafiltration under non-physiological conditions. Such was the extent of this work, that by the mid-83 
1990s there was a general consensus that protein binding was understood and it would be a further 84 
10-15 years before this was challenged16. Here, thanks to the work of Roberts and others17, who 85 
have highlighted the impact of sepsis on protein binding and the general potential for under dosing 86 
in those with severe sepsis, protein binding is again topical and important in dose optimisation 87 
strategies based on TDM18.  88 
 89 
From the mid-1990s, traditional approaches to antimicrobial TDM began to change. For 90 
aminoglycosides, discussions focused on the need to achieve high Cmax/MIC ratios to optimise 91 
efficacy and low troughs to reduce the risk of toxicity. Traditional 8 hourly dosage regimens were 92 
ƌĞƉůĂĐĞĚďǇ ?ŚŝŐŚĚŽƐĞ ?ĞǆƚĞŶĚĞĚŝŶƚĞƌǀĂů ?ƌĞŐŝŵĞŶƐĂŶĚƉĞĂŬĂŶĚƚƌŽƵŐŚŵŽŶŝƚŽƌŝŶŐďǇƐŝŶŐůĞ ?ŵŝĚ-93 
dose concentration measurements interpreted using a nomogram.8 The value of measuring peak 94 
vancomycin concentrations was questioned and new dosage guidelines reflected a change in the 95 
target range for trough concentrations.19   96 
 97 
During the 1990s, PK studies and reviews rarely reported data from healthy volunteers but instead 98 
examined the influence of clinical characteristics, such as renal replacement therapy,20 on drug 99 
handling and dose requirements. Over time, studies using population pharmacokinetic (PopPK) 100 
ŵĞƚŚŽĚŽůŽŐǇ ?ǁŚŝĐŚĐŽƵůĚŚĂŶĚůĞ ?ƐƉĂƌƐĞ ?ĐŽŶĐĞŶƚƌĂƚŝŽŶĚĂƚĂĨƌŽŵŵĂŶǇƉĂƚŝĞŶƚƐ ?ďĞŐĂŶƚŽƌĞƉůĂĐĞ101 
traditional PK studies that involved taking multiple blood samples from a small number of patients. 102 
This enabled research to be conducted using TDM data19 and in patients who were often excluded 103 
from traditional PK studies, such as paediatric patients and patients with renal impairment, liver 104 
disease, critical illness, burn injury, cystic fibrosis and malignant disease.  105 
 106 
From the mid-2000s to the present day, new laboratory techniques, such as liquid chromatography 107 
tandem-mass spectroscopy (LCMS), provided increased assay sensitivity and facilitated the 108 
quantification of free drug concentrations in plasma and interstitial fluid. Microdialysis techniques 109 
began to replace studies based on tissue homogenates and have led to a greater understanding of 110 
how clinical characteristics, such as obesity21, influence the distribution of antimicrobial agents. 111 
 112 
While papers continued to describe challenges associated with aminoglycoside and glycopeptide 113 
therapy, the paucity of new antibiotics and the development of resistant organisms stimulated the 114 
resurgence of older antimicrobial agents, such as colistin and polymyxin B. This led to the 115 
development of new assays to support PK studies designed to fill knowledge gaps around how best 116 
to use these agents.22 There was also an increase in research related to the TDM of other 117 
antimicrobial agents, particularly the beta-lactams, due to concerns about underdosing in critically ill 118 
patients.23 An increasing use of TDM for antifungal agents in clinical practice prompted to the 119 
publication of consensus guidelines in 2014.24   120 
 121 
Data analysis techniques have also progressed in recent years. While early PopPK studies focused on 122 
estimating PK parameters and identifying the clinical factors that influence these parameters, later 123 
studies used PopPK models to design dosage regimens for clinical use.19 More recently, PopPK 124 
models are being combined with Monte Carlo simulations to determine the antimicrobial dosage 125 
regimens with the highest probability of target attainment (PTA) or cumulative fraction of response 126 
(CFR) to achieve fT>MIC, fCmax/MIC or AUC0-24/MIC targets. The results of such studies have indicated 127 
that higher doses or prolonged infusions of beta lactam antibiotics are more likely to reach PKPD 128 
targets than traditional doses administered by bolus injection.25,26   129 
 130 
In the last 20 years we have witnessed a remarkable increase in the availability of new antiviral 131 
agents, in marked contrast to other antimicrobials, leading to major improvements in the 132 
management of HIV and hepatitis B and C infections. While initial studies tried to link efficacy or 133 
toxicity with trough concentrations of single agents,27 recent studies have considered the challenges 134 
of combination therapy28. These include using ritonavir to optimise therapy and reduce costs by 135 
boosting concentrations of protease inhibitors, and managing the complex interactions that arise 136 
with drug combinations used in the management of HIV positive patients co-infected with 137 
HCV/HBV,TB or malaria.29 Such challenges have enhanced international collaborations leading to 138 
high quality research being conducted in Africa and South East Asia, where large populations of 139 
patients suffer the burden of these diseases.  140 
 141 
Over the last 40 years, new drug assay and data analysis techniques have led to major improvements 142 
in our understanding of how to use antimicrobial agents effectively. With the current lack of 143 
economic incentives to develop new antibiotics, such methods are key to ensuring optimal use of 144 
both current and new antimicrobial agents. Future developments in this field are likely to 145 
incorporate pharmacogenetic data and physiologically based PK modelling techniques to improve 146 
the prediction of human outcomes from in vitro and animal data.  147 
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